Adiponectin, an adipokine primarily expressed in adipose tissue, plays a crucial role in insulin sensitivity and is involved in the pathogenesis of insulin resistance, type 2 diabetes, and the metabolic syndrome. Hypoadiponectinemia, caused by genetic and environmental factors, is a key contributor to these conditions. Adiponectin receptors, AdipoR1 and AdipoR2, mediate the antidiabetic effects of adiponectin and are downregulated in obesity-linked insulin resistance. Adiponectin and its receptors are potential therapeutic targets for obesity-related diseases. Adiponectin levels are reduced in obese individuals and those with insulin resistance, and lower levels are associated with increased risk of type 2 diabetes and the metabolic syndrome. Adiponectin improves insulin sensitivity and glucose metabolism by activating AMPK and PPARα, and its levels are influenced by factors such as diet, gender, and lifestyle. HMW adiponectin is the most active form and is strongly correlated with insulin sensitivity. The Adiponectin gene has several SNPs associated with insulin resistance and type 2 diabetes, including SNP 276, which is linked to reduced adiponectin levels and increased diabetes risk. Adiponectin receptors are expressed in various tissues, including skeletal muscle and liver, and their expression is decreased in obesity-linked insulin resistance. Adiponectin receptor agonists and upregulation of receptor expression are potential therapeutic strategies. Thiazolidinediones (TZDs) improve insulin resistance by increasing adiponectin levels and activating AMPK, and they may act through both adiponectin-dependent and -independent pathways. Adiponectin and its receptors are promising targets for the treatment of insulin resistance, type 2 diabetes, and the metabolic syndrome. Monitoring HMW adiponectin levels can serve as a predictive marker for these conditions. Future research may focus on enhancing or mimicking adiponectin action through modulation of adiponectin receptors.Adiponectin, an adipokine primarily expressed in adipose tissue, plays a crucial role in insulin sensitivity and is involved in the pathogenesis of insulin resistance, type 2 diabetes, and the metabolic syndrome. Hypoadiponectinemia, caused by genetic and environmental factors, is a key contributor to these conditions. Adiponectin receptors, AdipoR1 and AdipoR2, mediate the antidiabetic effects of adiponectin and are downregulated in obesity-linked insulin resistance. Adiponectin and its receptors are potential therapeutic targets for obesity-related diseases. Adiponectin levels are reduced in obese individuals and those with insulin resistance, and lower levels are associated with increased risk of type 2 diabetes and the metabolic syndrome. Adiponectin improves insulin sensitivity and glucose metabolism by activating AMPK and PPARα, and its levels are influenced by factors such as diet, gender, and lifestyle. HMW adiponectin is the most active form and is strongly correlated with insulin sensitivity. The Adiponectin gene has several SNPs associated with insulin resistance and type 2 diabetes, including SNP 276, which is linked to reduced adiponectin levels and increased diabetes risk. Adiponectin receptors are expressed in various tissues, including skeletal muscle and liver, and their expression is decreased in obesity-linked insulin resistance. Adiponectin receptor agonists and upregulation of receptor expression are potential therapeutic strategies. Thiazolidinediones (TZDs) improve insulin resistance by increasing adiponectin levels and activating AMPK, and they may act through both adiponectin-dependent and -independent pathways. Adiponectin and its receptors are promising targets for the treatment of insulin resistance, type 2 diabetes, and the metabolic syndrome. Monitoring HMW adiponectin levels can serve as a predictive marker for these conditions. Future research may focus on enhancing or mimicking adiponectin action through modulation of adiponectin receptors.